Firma Immunic, Autor bei Presse-Blog

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

6. August 202113. Dezember 2023 Firma ImmunicFinanzen / Bilanzen4sc, caldose, cancer, gtthe, immunic, imu, ltem, ltli, ltp, ltstrong, ltul, quotdisc, rrms, thymocyte, with

– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis – – Reported In Vitro Data Showing That IMU-935 May Inhibit the Generation of Mehr

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

20. Juli 202113. Dezember 2023 Firma ImmunicFinanzen / Bilanzenaegis, clinical, financial, fiscal, immunic, immunic's, imu, prospectus, report, revenue, roth, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common Mehr

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

15. Juli 202113. Dezember 2023 Firma ImmunicFinanzen / Bilanzenaegis, clinical, financial, fiscal, immunic, immunic's, imu, prospectus, report, revenue, roth, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 4,500,000 shares of its Mehr

Immunic, Inc. Announces Proposed Public Offering of Common Stock

15. Juli 202113. Dezember 2023 Firma ImmunicFinanzen / Bilanzenclinical, financial, fiscal, immunic, immunic's, imu, market, prospectus, report, revenue, risks, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell shares of its common stock Mehr

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

1. Juli 202113. Dezember 2023 Firma ImmunicForschung und Entwicklungbrain, calvid, dosing, immunic, immunic's, imu, market, neurofilament, patients, ppms, revenue, rrms, statements, unblinded, with

. – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval – Supportive Phase 2 CALLIPER Trial in Progressive Multiple Mehr

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

1. Juni 202113. Dezember 2023 Firma ImmunicForschung und Entwicklungclinical, fiscal, immunic, immunic's, imu, market, mba, merck, new, project, report, revenue, securities, statements, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh Mehr

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

6. Mai 202113. Dezember 2023 Firma ImmunicFinanzen / Bilanzen4sc, caldose, calvid, fiscal, immunic, immunic's, imu, market, patients, revenue, rrms, statements, unblinded, vaccines, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity. "Our clinical program Mehr

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

31. März 202113. Dezember 2023 Firma ImmunicBiotechnik??royalties??, 4sc, cancer, domatinostat, fiscal, immunic, immunic's, imu, market, revenue, rrms, securities, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic Mehr

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

26. Februar 202113. Dezember 2023 Firma ImmunicForschung und Entwicklungcaldose, calvid, dosing, immunic, immunic's, imu, liver, market, patients, revenue, rrms, statements, syndrome, unblinded, with

Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021 Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis Announced Main Analysis of Phase Mehr

Immunic, Inc. Added to NASDAQ Biotechnology Index

14. Dezember 202013. Dezember 2023 Firma ImmunicForschung und Entwicklungclinical, etf, etfs, fiscal, ibb, immunic, immunic's, imu, index??, ishares, market, revenue, securities, statements, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective Mehr

Autor: Firma Immunic